A new clinical trial published on ClinicalTrials.gov is underway to better understand how indolent systemic mastocytosis (SM) affects people and how it is managed.
Indolent SM is the most common form of SM, accounting for around 75%-90% of cases. In this condition, the body makes too many mast cells. While these cells are part of the immune system, their excessive activation leads to chronic symptoms similar to severe allergic reactions.
Now, researchers at Blueprint Medicines Corporation are running a study to collect detailed information on symptoms, complications such as allergic reactions and bone problems, quality of life and how indolent SM is treated — including the use of avapritinib — to help improve future care for people living with the condition.
Adults ages 18 and older with indolent SM may be able to join this study if they are being treated, or plan to be treated, for indolent SM with symptom-relief medicines and/or avapritinib. People cannot join if they have a more advanced form of SM, a related blood cancer, or smoldering SM, if they are taking part in another clinical trial for SM, or if they are using a KIT-inhibitor medicine other than avapritinib.
Read more about SM signs and symptoms
The researchers plan to enroll 150 people with indolent SM, and the trial is expected to run from February 2026 to December 2032.
If you agree to take part, you may be asked to give a blood or tissue sample. Your sample would be stored in a secure research lab and used to learn more about what causes ISM, related health problems and how treatments can be improved. Your name or other personal details would be removed from the sample so that no one studying it will know who you are.
Sign up here to get the latest news, perspectives, and information about SM sent directly to your inbox. Registration is free and only takes a minute.
